Text

Efficacy of Roxithromycin in Acute Bronchitis (Efektivitas Roksitromisin pada Bronkitis Akut)

---

The study of efficacy of roxithromycin in 99 acute bronchitis patients had been conducted in three hospitals in Jakarta. Roxithromycin 300 mg single doses was administered for 5 days, and was followed by roborantia for 9 days, thus in there were 14 days of observation. The study found that the cure rate was 78.79 percent, clinical improvement rate was 85.86 percent and relaps rate was 7.06 percent. Several studies in other countries showed that roxithromycin 300 mg single dose for 7-10 days, produced better efficacy than this study that used only 5 days of treatment. The study also found that there was no serious side effects which were caused by roxithromycin, except the mild side effects such as headache, nausea and mialgia in 11 cases that need no treatment at all. Serological examination was performed in 92 patients, and it was found that there were acute atypical bacteria infection (IgM+) in 40 cases (43.48 percent), which consist of Mycoplasma pneumoniae infection in 21 cases (22.83 percent), Chlamydia spp. infection in 13 cases (14.13 percent) and mix-infection with Chlamydia spp. and M. pnemoniae in 6 cases (6.52 percent). This study concluded that roxithromycin 300 mg single dose for 5 days in god for treating acute bronchitis. Although it produced quite good results, the follow up study to evaluate the optimal treatment using roxithromycin should be carried out, since this study showed that the relaps rate was plus/minus 7.06 percent and the other studies showed that the longer duration of treatment (more than 5 days) produced better results.

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

Majalah Kedokteran Indonesia,46(10)1996:545-548

Penerbit

: ., 1996

Deskripsi Fisik

-

Bahasa

ISBN/ISSN

-

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

bronchitis
roxithromycin

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar